Newer, safer nonsteroidal anti-inflammatory drugs: Rational NSAID selection for arthritis

Canadian Family Physician

Volumn 44, Issue JAN., 1998, Pages 101-107

  Bensen, William ^a   Zizzo, Angelo ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTHROTEC; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; ETODOLAC; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; MISOPROSTOL; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTAGLANDIN; TIAPROFENIC ACID;

ARTHRITIS; ARTICLE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL DISEASE; HUMAN; KIDNEY DISEASE; ORAL DRUG ADMINISTRATION; TABLET;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ARTHRITIS; BUTANONES; DRUG THERAPY, COMBINATION; ETODOLAC; HUMANS; MISOPROSTOL;

EID: 17044443700     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Arthritis Society of Canada. First quarter booklet Toronto: The Arthritis Society of Canada; 1995.
2. Statistics Canada. Population projections for Canada, provinces and territories (1993-2016). Ottawa: Statistics Canada; 1991 Cat No. 91 520.
3. Tannenbaum H, Davis P, Russell AS, Atkinson MH, Maksymowych W, Huang SHK, et al. An evidence-based approach to prescribing NSAIDs in musculoskelatel disease: a Canadian consensus. Can Med Assoc J 1996; 155(1):77-88.
4. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs - differences and similarities. N Engl J Med 1991;324 (24):1719-24.
5. Lanza FL. A review of gastric ulcer and gastroduodenal injury in normal volunteers receiving aspirin and other non-steroidal anti-inflammatory drugs. Scand J Gastroenterol Suppl 1989;163(Suppl):24-31.
6. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987;82:1153-8.
7. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995;123:241-9.
8. Kaplan B, Swain RA. NSAIDs. Are there any differences? Arch Fam Med 1993;2:1167-74.
9. ArthroScope. Toronto: The Arthritis Society; 1995.
10. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991;115:787-96.
11. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol Suppl 1991;18(Suppl 28):6-10.
12. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257-63.
13. Silverstein FE, Gilbert DA, Tedesco FJ, Buenger NK, Persing J. The national ASGE survey on upper gastrointestinal bleeding: II. Clinical prognostic factors. Gastrointest Endosc 1981;27:80-93.
14. Murray MD, Brater DC. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Am Rev Pharmacol Toxicol 1993;33:435-65.
15. Ehsanullah RS, Page MC, Tildealey G, Wood JR. Prevention of gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ 1988;297:1017-21.
16. Agrawal NM, Roth S, Graham DY, White RH, Germain B, Brown JA, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial. Ann Intern Med 1991;115:195-200.
17. Oddsson E, Gudjonnsson H, Thjodleifsson B. Protective effect of omeprazole or ranitidine against naproxen induced damage to human gastroduodenal mucosa. Abstracts of the World Congresses of Gastroenterology. Sydney: Medical Group (UK), Ltd, Abingdon; 1990. p. 22.
18. McKenna F. Review of Arthrotec clinical data. Eur J Rheumatol Inflamm 1994;14(Suppl 3):12-6.
19. Geis GS. Overall safety of Arthrotec. Scand J Rheumatol Suppl 1992;96 (Suppl):33-6.
20. Caruso I, Bianchi Porro G. Gastroscopic evaluation of anti-inflammatory agents. BMJ 1980;280:75-8.
21. Garcia-Rodriguez LA, Walker AM, Perez-Gutthann S. Nonsteroidal antiinflammatory drugs and gastrointestinal hospitalizations in Saskatchewan: a cohort study. Epidemiology 1992;3:337-42.
22. Levy RA, Smith DL. Clinical differences among nonsteroidal antiinflammatory drugs: implications for therapeutic substitution in ambulatory patients. Drug Intell Clin Pharm 1989; 23:76-85.
23. Glaser KM. Cyclooxygenase selectivity and NSAIDs. Cyclooxygenase-2 selectivity of etodolac (Lodine). Inflammopharmacol 1995;3:1-12.
24. Dandona P, Jeremy JY. Nonsteroidal anti-inflammatory drug therapy and gastric side effects. Does nabumetone provide a solution? Drugs 1990;40(Suppl 5):16-24.
25. Laine L, Sloane R, Ferretti M, Cominelli F. A randomized, double-blind comparison of placebo, etodolac and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest Endosc 1995;42:428-33.
26. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994;91:3228-32.
27. Bianchi Porro G, Caruso I, Montrone MPF, Ardizzone S. A double-blind gastroscopic evaluation of the effects of etodolac and naproxen on the gastrointestinal mucosa of rheumatic patients. J Intern Med 1991;229:5-8.
28. Roth SH. Endoscopy-controlled study of the safety of nabumetone compared with naproxen in arthritis therapy. Am J Med 1987;83:25-30.
29. Lanza FL. Gastrointestinal toxicity of newer NSAIDs. Am J Gastroenterol 1993;88:1318-23.
30. Serni U. Global safety of etodolac: reports from worldwide postmarketing surveillance studies. Rheumatol Int 1990; 10(Suppl):23-7.
31. Berhard G. Worldwide safety experience with nabumetone J Rheumatol Suppl 1992;19(Suppl):48-56.
32. Ferrez M, Maetzel A, Bombardier C. Meta-analysis comparing the effects of low risk nonsteroidal anti-inflammatory drugs (NSAIDs) on the gastric and duodenal mucosa [abstract]. Arthritis Rheum 1995;38(9 Suppl):S261.
33. Schnitzer T. The International Conference on Inflammapharmacology. San Francisco; 1997 March 17-19.